Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers
- Conditions
- Frozen Embryo Transfer
- Interventions
- Diagnostic Test: Primary and secondary hemostasis
- Registration Number
- NCT04359576
- Lead Sponsor
- Horsens Hospital
- Brief Summary
The study focus on the impact of estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in women undertaking assisted reproductive technology treatment (ART).
- Detailed Description
The aim is to investigate whether the coagulation is activated in women undergoing estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in assisted reproductive technology treatment (ART). An activation of the coagulation might induce an increased thromboembolic risk in these women. Thus, the present study may lead to improvement of the current treatment protocol for women receiving AC-FET and ultimately prevent thromboembolic complications for woman in fertility treatment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 50
- Women receiving FET with or without estrogen/progesterone substitution
- Known bleeding disorder
- Indication for thromboprophylaxis during ART treatment
- Treatment with anti-platelet medication including non-steroid-anti-inflammatory drugs (NSAIDs) within the last week
- Donor recipients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description FET Primary and secondary hemostasis Estrogen/progesterone substituted and natural cycles
- Primary Outcome Measures
Name Time Method coagulation 1 year Primary and secondary hemostasis parameters
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Horsens Regional Hospital
🇩🇰Horsens, Denmark